Table 4.
Prognostic factor analysis of 39 patients treated with FOLFIRINOX as a second-line treatment
| Variable | Progression-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Median, months (95% CI) | Univariate (p value) | Multivariate hazard ratio (p value) | Median, months (95% CI) | Univariate (p value) | Multivariate hazard ratio (p value) | |
| Age | ||||||
| ≤ 60 years | 2.3 (0.89–3.71) | 0.209 | 0.565 (0.193) | 8.5 (3.39–13.61) | 0.514 | 0.563 (0.209) |
| > 60 years | 4.83 (2.15–7.51) | 8.63 (5.58–11.69) | ||||
| Sex | ||||||
| Male | 3.3 (1.28–5.32) | 0.827 | 8.5 (4.49–12.51) | 0.854 | ||
| Female | 3.73 (0–9.46) | 8.83 (5.24–12.42) | ||||
| Extent of disease | ||||||
| Locally advanced | 1.77 (0–4.22) | 0.465 | 1.318 (0.616) | 9.67 (7.22–12.12) | 0.14 | 0.379 (0.05) |
| Metastatic | 4.7 (1.86–7.54) | 6.37 (3.56–9.18) | ||||
| Primary tumor location | ||||||
| Head | 4.7 (0.51–8.89) | 0.332 | 0.711 (0.399) | 8.83 (5.55–12.11) | 0.569 | 0.862 (0.719) |
| Body or tail | 2.9 (1.44–4.36) | 7.6 (1.74–13.46) | ||||
| Liver metastasis | ||||||
| Yes | 6.53 (2.04–11.02) | 0.414 | 0.642 (0.29) | 6.37 (2.94–9.8) | 0.459 | 1.052 (0.897) |
| No | 2.9 (0–6.19) | 8.67 (8.18–9.16) | ||||
| CA19-9 value (U/mL) | ||||||
| > 10 times of UNL | 3.93 (1.52–6.35) | 0.972 | 8.5 (5.51–11.49) | 0.653 | ||
| ≤ 10 times of UNL | 3.77 (1.17–6.37) | 8.83 (2.66–14.99) | ||||
CA19-9 carbohydrate antigen 19-9, UNL upper normal limit